Published in Metab Brain Dis on April 12, 2015
Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol (2006) 7.75
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci (2009) 3.77
Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 3.31
Electron transport chain defects in Alzheimer's disease brain. Neurology (1994) 2.51
Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2010) 2.45
A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol (2010) 1.68
Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm (Vienna) (1998) 1.44
Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology (2001) 1.17
Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. PLoS One (2014) 1.13
Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol (2009) 1.12
Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis (2011) 1.10
Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol (1999) 1.09
Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem. Antioxid Redox Signal (2007) 1.09
From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol Neurobiol (2012) 1.07
Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A (1986) 1.06
Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen (2011) 1.00
Presenilin transgenic mice as models of Alzheimer's disease. Brain Struct Funct (2009) 0.98
Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol (2013) 0.96
Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease. Ann Neurol (1987) 0.91
Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. FEBS Lett (1994) 0.91
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med (2013) 0.87
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. J Neurol Sci (2013) 0.86
1H NMR metabolomic signatures in five brain regions of the AβPPswe Tg2576 mouse model of Alzheimer's disease at four ages. J Alzheimers Dis (2014) 0.83
1H-proton magnetic resonance spectroscopy differentiates dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis (2014) 0.81
Hippocampal neurochemical changes in senescent mice induced with chronic injection of D-galactose and NaNO₂: an in vitro high-resolution NMR spectroscopy study at 9.4T. PLoS One (2014) 0.79
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Uric acid as a CNS antioxidant. J Alzheimers Dis (2010) 1.93
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol (2002) 1.79
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke (2004) 1.63
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis (2008) 1.40
Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging (2005) 1.39
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis (2005) 1.39
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One (2011) 1.32
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics (2007) 1.31
Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol (2003) 1.30
Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med (2010) 1.27
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res (2006) 1.20
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
Retirement patterns from career employment. Gerontologist (2006) 1.16
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis (2013) 1.12
L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis (2010) 1.10
Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. FASEB J (2005) 1.06
F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal (2005) 1.04
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol (2011) 1.04
Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity. J Alzheimers Dis (2008) 0.99
Ascorbic acid and rates of cognitive decline in Alzheimer's disease. J Alzheimers Dis (2009) 0.98
Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis (2008) 0.98
Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol (2012) 0.95
Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem (2009) 0.95
Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine. Biochim Biophys Acta (2011) 0.94
Dyslipidemia and blood-brain barrier integrity in Alzheimer's disease. Curr Gerontol Geriatr Res (2012) 0.94
Reliability and validity of food frequency questionnaire and nutrient biomarkers in elders with and without mild cognitive impairment. Alzheimer Dis Assoc Disord (2011) 0.93
Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol (2010) 0.93
Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res (2005) 0.93
Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J Alzheimers Dis (2010) 0.93
Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol Cell Proteomics (2011) 0.92
ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiol Aging (2012) 0.91
Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology (2013) 0.90
Phytic acid as a potential treatment for alzheimer's pathology: evidence from animal and in vitro models. J Alzheimers Dis (2011) 0.89
CCR6: a biomarker for Alzheimer's-like disease in a triple transgenic mouse model. J Alzheimers Dis (2010) 0.89
Cognitive profile of LRRK2-related Parkinson's disease. Mov Disord (2015) 0.87
Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2014) 0.86
People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Mov Disord (2014) 0.86
Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action. Int J Alzheimers Dis (2012) 0.85
Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2012) 0.84
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. Dis Model Mech (2011) 0.82
MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Dis Assoc Disord (2009) 0.82
Review of selected databases of longitudinal aging studies. Alzheimers Dement (2012) 0.82
Memory, mood, and vitamin D in persons with Parkinson's disease. J Parkinsons Dis (2013) 0.81
Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future. Aging health (2008) 0.80
The blood-brain barrier and microvascular water exchange in Alzheimer's disease. Cardiovasc Psychiatry Neurol (2011) 0.79
Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J Alzheimers Dis (2005) 0.78
Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatment. Brain Res (2002) 0.76
Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiol Aging (2013) 0.75
Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. Mov Disord (2012) 0.75